Leafy green vegetables may slow mental deterioration
the ONA take:
According to a preliminary findings presented at the annual meeting of the American Society for Nutrition in Boston, Massachusetts, researchers from Rush University Medical Center in Chicago, Illinois, have found that a single serving of leafy green vegetables each day may slow dementia.
For the study, researchers identified 954 men and women enrolled in Rush's Memory and Aging Project. Participants had a mean age of 81 at the time of study initiation and 75% were women. Participants completed a 144-item food and beverage questionnaire and underwent 19 mental skills tests every year for an average of about 5 years.
Results showed that those who consumed one or two servings of leafy green vegetables every day had a mental capacity of someone more than 10 years younger, compared with those who never ate leafy green vegetables, such as spinach, kale, mustard greens, and collards.
Green leafy vegetables are rich in vitamin K, but also contain lutein, folate, and beta-carotene. It is unclear what the mechanism is behind the association between green leafy vegetable consumption and slower mental deterioration.
Researchers have found that a single serving of leafy green vegetables each day may slow dementia.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|